Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus

Pharmaceutical Executive May 21, 2025
Don Tracy, Associate Editor

Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.

Results from the Phase II WILLOW study show that enpatoran, Merck’s investigational oral TLR7/8 inhibitor, demonstrated a statistically significant dose-response and clinically meaningful reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active lupus rash. The findings, from Cohort A of the study will be presented at the 16th International Congress on Systemic Lupus Erythematosus.¹

Could Enpatoran Offer a New Treatment Path for Lupus Patients?

“Lupus can make navigating everyday life difficult,” said Jan Klatt, head, development unit, neurology &...

Today's Sponsors

Today's Sponsor